Chimerix, Inc. Announces Completion Of Public Offering Of Common Stock And Exercise In Full Of Option To Purchase Additional Shares Of Common Stock

DURHAM, N.C., May 27, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the completion of an underwritten public offering of 8,395,000 shares of its common stock, including 1,095,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Chimerix at a price to the public of $14.22 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, were approximately $119.4 million. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.

Help employers find you! Check out all the jobs and post your resume.